Check out @EuroInterventio Turning Point episode 2 with @rallamee 🎧 https://t.co/DCCBjYTXEr @DFCapodanno @PCRonline @ShrillaB @mirvatalasnag @WomenAs1 @rajkumar_chris @ProfDFrancis @MikeFoley89 @fiyyazAJ @ShaynaChotai @FloSimader @mshunshin @NievesGonzalo1 @nickaram @Hragy

Michael foley presenting orbita 2 analysis showing that ffr and ifr predict angina benefit from pci. Absolute values matter more than dichotimous cutoff. I would personally like to see how microvascular function fits into this @rallamee @mirvatalasnag @OKhaliqueMD @Hragy

🔥🔥🔥

Watch This Week's Episode of OPCI Journal Club: “ORBITA-STAR Trial and the ORBITA II Symptoms Analysis” presented by @rallamee @rajkumar_chris and @FloSimader. Joined by panelists @djc795 @JWMoses @ESHLOF and Dr. Lawrence Garcia. https://t.co/UGxktZwTiL #cardiotwitter

Just in case you thought the ORBITA team had gone on summer vacation… The first ORBITA-MOON case was completed yesterday. Another n-of-1 trial that might have some interesting results. Well done @ShaynaChotai on achieving the first of many big milestones during your PhD!

#cvCAD patients who have angina are more likely to achieve symptom relief from #PCI, according to an analysis of the ORBITA-2 trial in #JACC. https://t.co/9oip2X4K2J @TCTMD @TCTMD_Caitlin

Merci Paris and #euroPCR for an incredible week and experience with the best Team and colleagues✨ @rallamee @JACCJournals @PCRonline

ORBITA-2: Angina Phenotype Strongly Predicts PCI Response @rallamee @FloSimader https://t.co/g4at0uY87V

So grateful and proud to have such an incredible mentor and role model @rallamee ✨

.@FloSimader on #ORBITA-2 at #EuroPCR: 📌Poor correlation between symptoms & disease severity 📌Symptom nature is a powerful predictor of the placebo-controlled efficacy of #PCI 📌Rose angina & typical angina are excellent predictors of the placebo-controlled efficacy of PCI

#ICYMI @aayshacader asked @rallamee & @FloSimader to summarize the symptom-stratified analysis of ORBITA-2 presented at #EuroPCR!

The symptom stratified analysis of ORBITA2 and the ORBITA-STAR trial both presented at #EuroPCR2024 and simultaneously published in @JACCJournals by @FloSimader and @rajkumar_chris. PCI isn’t a therapy for all symptoms, it’s a therapy for angina @rallamee @mshunshin

🔥 Important new insights from ORBITA-2 study presented today at #EuroPCR 👉🏼 More angina symptoms do not necessarily reflect more extended coronary disease 👉🏼 The clinical history is a strong predictor of the efficacy of PCI 🚨Interroge your patients! @PCRonline @rallamee

#EuroPCR #JACC LBCT SimPub: #ORBITA-2 symptom-stratified analysis - Although symptom severity & nature were poorly associated with disease severity, the nature of symptoms powerfully predicted the placebo-controlled efficacy of #PCI. https://t.co/gTBH37zmyo @FloSimader @rallamee

…and this: O R B I T A 2: symptom-stratified analysis ⏰ 15/05 8:30 📍 Theatre Havane 👋 Florentina Simader @rallamee

Impact not impact factor - a new vision from @hmkyale for the new #JACC

Q: Does blinding matter in RCTs of surgical procedures? A: Depends on the endpoint @JAMASurgery We compared placebo-controlled and open-label surgical trials to identify when the placebo effect is most powerful @rallamee @KatieEljadi @ImperialNHLI https://t.co/CWdvfyQaJ0

Delighted to bring our EAPCI Journal club to 🇬🇧 Discussing #ORBITA2 and the fantastic work by the team: @rallamee @rajkumar_chris @MikeFoley89 @fiyyazAJ @FloSimader @ProfDFrancis

Goodbye #ACC from the ORBITA team. Thank you for featuring our work and see you again next year! @FloSimader @ShaynaChotai @MikeFoley89 @rajkumar_chris @fiyyazAJ @mshunshin